Associated Papers
Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
Yari A et al.
Journal of Gastrointestinal Cancer, 2021
Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV et al.
Genome Medicine, 2016
A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D et al.
Oncotarget, 2015
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S et al.
Medical Oncology (northwood, London, England), 2014
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.
Tol J et al.
Journal of Cellular and Molecular Medicine, 2010
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.
Oden-Gangloff A et al.
British Journal of Cancer, 2009
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
Perrone F et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2009
Select a paper to view details